AI in Regulatory Submissions: How FDA, EMA, and Global Authorities Are Leading the Change

Remember the old days of regulatory submissions? You’d spend months compiling documents by hand, double-checking every cross-reference, running endless quality checks. It was exhausting.

AI and machine learning are changing everything—and here’s the surprising part: regulators are the ones pushing this forward. The FDA, EMA, and other health authorities aren’t just accepting AI; they’re actively building it into how they work.

If you’ve been in this field for a while, you know the pain points: tight deadlines that seem impossible, regulations that change depending on which country you’re submitting to, and zero room for error.

But here’s some good news: regulators around the world are introducing AI tools that will change both sides of the equation—how you prepare submissions and how they review them.

How Regulators Are Using AI?

ELSA: The FDA’s AI Assistant

In June 2025, the FDA launched ELSA (Electronic Language System Assistant). It’s an internal AI tool that helps FDA staff work faster and smarter—from reviewers analyzing your clinical data to field investigators.

The results have been impressive. FDA Commissioner Dr. Marty Makary said tasks that used to take days now take minutes. One reviewer reported cutting a 2-3 day task down to just 6 minutes (Source).

ELSA is helping speed up clinical protocol reviews and identify which sites need inspections most urgently.

But here’s what you need to know: ELSA isn’t perfect. Some FDA staff have reported that it occasionally “hallucinates” – for example, inventing studies that don’t exist or getting research details wrong.

Importantly, ELSA currently runs on FDA’s secure internal cloud and does not have access to the actual industry submissions you send in. In other words, it’s a powerful assistant for FDA employees, but final decisions are still firmly in human hands.

CDRH-GPT for Medical Devices

The FDA is also testing another tool called CDRH-GPT specifically for the Center for Devices and Radiological Health. This one’s designed to help with medical device reviews, showing the FDA is serious about bringing AI into the review process itself.

The EMA’s AI-Powered Ecosystem

What the EMA Is Doing in Europe

The European Medicines Agency has been just as ambitious with AI, rolling out several tools that are already up and running:

Scientific Explorer: Launched in 2024, this AI tool helps EMA staff search through scientific information quickly and accurately. It’s particularly useful during scientific advice procedures, basically making it faster to find the exact information they need.

Safety Monitoring Tools: The EMA has built AI tools specifically for tracking drug safety:

• EurEKA automatically pulls adverse reaction data from reports, saving staff from doing it manually.
• ERATO scans scientific literature using generative AI to catch potential safety issues early.

The EMA also runs an AI Observatory that tracks what’s working across Europe. For example, Sweden uses a tool called M-RECON to match documents, and Denmark has PHAIR for monitoring vaccine safety in real time. The EMA is paying attention to these local innovations and learning from them.

The UK’s Approach

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has rolled out two AI tools that are already making a difference:

• Knowledge Hub lets assessors search through past applications to find common problems. This means they can give you better guidance earlier in the process, before issues become roadblocks.
• GMP Compliance Checker scans manufacturing documents in seconds—work that used to take experts hours. It automatically flags compliance issues for human reviewers to check, freeing up regulators to focus on the complex safety questions that really need their expertise.

The Common Theme Worldwide

Whether it’s Health Canada emphasizing that humans must stay in control of AI decisions, or Japan’s PMDA exploring ways for AI systems to keep learning and improving, the pattern is consistent across all these agencies.

AI is making regulatory work faster and more efficient. But every agency agrees: human judgment stays at the center, and transparency isn’t optional.

What This Actually Means for Your Day-to-Day Work

This isn’t just about fancy technology. It’s about getting treatments to patients faster and making your job more manageable.

• You’ll Spend Less Time on Assembly: AI systems can automatically pull data from multiple sources and compile it for you. We’re talking about cutting assembly time by 60-80%. That means weeks of work condensed into days.
• Fewer Errors Slipping Through: Here’s the thing about AI: it doesn’t get tired at 5 PM on a Friday. It maintains the same level of attention whether it’s reviewing page 1 or page 10,000. Those small discrepancies that are easy to miss when you’re exhausted? AI catches them.
• Catching Problems Before You Submit: Advanced analytics can spot potential compliance issues before your submission even goes out the door. Instead of getting questions back from the agency weeks later, you can fix problems up front. It’s like having an extra set of expert eyes on your work.
• Working Together Differently: Cloud-based AI platforms are changing how you interact with regulators. Instead of static document dumps, you can exchange data more dynamically. It’s a smoother, more collaborative process than the old way of doing things.

Where Do We Go from Here?

AI isn’t a “someday” technology anymore—it’s here, and it’s quickly becoming standard practice.

The regulatory professionals who learn to use these tools strategically will have a real advantage. They’ll navigate complex submissions more smoothly, get products through the pipeline faster, and ultimately help get safe, effective treatments to patients who are waiting for them.

But here’s the important part: this isn’t about replacing people with machines. It’s about balance. Let AI handle the heavy lifting with data—the searching, the scanning, the pattern recognition. But keep human judgment, ethics, and expertise exactly where they belong: in charge.

The tools are getting better every day. The question is: how will you use them?